Is Corcept Therapeutics Fairly Priced After Recent Partnership and 54.7% Share Surge in 2025?

• Wondering if Corcept Therapeutics is really worth its recent buzz, or if the market might be missing something about this fast-growing biotech? You are not alone. This article provides a deep dive into the company.
• Shares have delivered an impressive 54.7% gain so far this year, adding to a strong 196.1% return over three years and a phenomenal 236.2% over five, hinting at momentum and rising optimism among investors.
• The recent surge has been fueled by positive updates in the company’s pipeline and substantial progress in the regulatory space. A new partnership announced last month and advancements in clinical trials have added to the sense of opportunity and possibly risk that is driving price action.
• When it comes to valuation, Corcept Therapeutics currently scores a 3 out of 6 on our core value checks, signaling there is plenty to discuss. Up next, we will walk through multiple methods to see where the numbers and something you will not find on a typical scorecard line up for Corcept.

Corcept Therapeutics delivered 34.3% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: Corcept Therapeutics Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow (DCF) model estimates a company's intrinsic value by projecting its expected future cash flows and discounting them back to today's value. This method helps investors assess whether a stock is trading above or below what those future cash flows are worth in present dollars.

For Corcept Therapeutics, the most recent Free Cash Flow reported was $162.4 million. Analysts have forecasted continued robust growth, with Free Cash Flow projected to reach $706.7 million by 2029. Public analyst estimates go out for five years, while projections beyond that are extrapolated using established methodologies to offer a full picture of possible cash flow growth. By 2035, annual discounted Free Cash Flow could reach over $781 million, indicating sustained performance potential.

Based on the DCF approach, the estimated intrinsic value of Corcept Therapeutics stands at $259.75 per share. This figure implies a 70.2% discount to the company’s current market price, suggesting that shares may be considerably undervalued relative to fundamental cash flows.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Corcept Therapeutics is undervalued by 70.2%. Track this in your watchlist or portfolio, or discover 928 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Corcept Therapeutics.

Approach 2: Corcept Therapeutics Price vs Earnings

For companies like Corcept Therapeutics that are generating profits, the Price-to-Earnings (PE) ratio is widely used to gauge valuation. The PE ratio offers a quick way to see how much investors are willing to pay for each dollar of earnings, making it a useful metric for profitable businesses.

Growth expectations and risk are key drivers of what is considered a reasonable or "fair" PE ratio. Higher growth prospects often justify a higher PE, while elevated risks, such as competitive threats or regulatory hurdles, can push it lower. In Corcept’s case, the current PE ratio stands at 77.68x. This is significantly higher than the pharmaceuticals industry average of 19.92x and the peer average of 40.21x. This suggests the market is placing a premium on Corcept’s future potential.

Simply Wall St's proprietary "Fair Ratio" goes beyond industry and peer averages by accounting for the company's specific factors, such as earnings growth, profit margins, risks, size, and sector dynamics. For Corcept, the Fair Ratio is calculated as 68.24x. This approach aims to reflect a multiple that is more tailored to the stock's actual prospects, rather than relying solely on broad market comparisons.

When we line up Corcept’s actual PE ratio of 77.68x with the calculated Fair Ratio of 68.24x, the difference is notable. While the market appears optimistic about Corcept’s future growth, the current valuation looks a bit stretched relative to its fundamentals as assessed by the Fair Ratio.

Result: OVERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1432 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Corcept Therapeutics Narrative

Earlier we mentioned that there's an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is a simple, approachable framework where you tell your story about a company by connecting your views on its future growth, earnings, and margins to a financial forecast. This process then leads to your own estimate of fair value.

Unlike static ratios or generic valuation methods, Narratives connect the company’s real-world story through what you believe about its pipeline, risks, and execution, to a dynamic financial model. This approach is not just for professionals; it is available to everyone on Simply Wall St’s Community page, where millions of investors use Narratives to make smarter decisions.

Narratives empower you to see in real time whether Corcept Therapeutics appears to be overvalued or undervalued by comparing your fair value calculation with the current share price. They automatically update as new data or news emerges, ensuring your outlook always stays current.

For example, some investors might form a Narrative based around rapid new drug approvals and forecast a fair value as high as $145.0. Others, more concerned about competition and margin pressures, may arrive at a conservative $121.0. This demonstrates how your outlook can directly shape your investment decisions.

Do you think there's more to the story for Corcept Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com